---

On February 25, 2021, Compugen Ltd. (the “Company”) issued a press release announcing a data update from the Company’s COM701 Phase 1 clinical trial, a copy of which is furnished as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.

The information contained in the first, fourth, fifth, sixth and seventh paragraphs and the section titled “Forward-Looking Statement” in the Press Release attached as Exhibit 99.1 is hereby incorporated by reference into the Company’s Registration Statement on Form F-3, File No. 333-240183.

On February 25, 2021, the Company also issued a press release reporting the Company’s fourth quarter and full year 2020 results, a copy of which is furnished as Exhibit 99.2 to this Report on Form 6-K.

The information included in this Report on Form 6-K (including Exhibit 99.2 hereto) that is furnished shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Report on Form 6-K (including Exhibit 99.2 hereto) that is furnished shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

---